Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 13/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4108833 | 1.00 | PFKFB3 (0.46) | PFKFB3LMNAL3MBTL1ALDH1A1TSHR | |
| SCHEMBL1616137 | 0.80 | PFKFB3 (0.42) | PFKFB3EGFR | |
| SCHEMBL1616136 | 0.80 | PFKFB3 (0.42) | PFKFB3EGFR | |
| SCHEMBL3403995 | 0.76 | FADS1 (0.55) | PFKFB3LMNAALDH1A1TSHREGFR | |
| SCHEMBL3401133 | 0.76 | FADS1 (0.43) | PFKFB3LMNAEGFR | |
| SCHEMBL3404143 | 0.76 | FADS1 (0.43) | PFKFB3LMNAEGFR | |
| SCHEMBL3404459 | 0.76 | FADS1 (0.43) | PFKFB3LMNAEGFR | |
| SCHEMBL4106465 | 0.76 | FADS1 (0.43) | PFKFB3LMNAEGFR | |
| SCHEMBL3407115 | 0.76 | FADS1 (0.43) | PFKFB3LMNAEGFRMAPK14 | |
| SCHEMBL4098481 | 0.76 | FADS1 (0.43) | PFKFB3LMNAEGFRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188284-B2 | 2-aminoquinolines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | claimed |
| US-20090227583-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-09-10 | — | — | US | claimed |
| US-8188284-B2 | 2-aminoquinolines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2252372-A1 | 2-AMINOQUINOLINES | F. Hoffmann-La Roche AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009109502-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227583-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227583-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2B | PFKFB3 3870/4885LMNA 3773/4885L3MBTL1 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.